Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy

Karasu, Nilgun; Akalın, Hilal; Gökçe, Nuriye; Yildirim, Abdulbaki; Demir, Mikail; Kulak, Hande; Çelik, Serhat; Keklik, Muzaffer; Dündar, Munis

doi:10.1007/s12032-021-01571-1

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both IL-6 and TNF-α are critical cytokines and important inflammatory mediators involved in various physiological and immune processes. It has been reported that patients with acute leukemia exhibit abnormally elevated IL-6 and TNF-α levels, which are associated with their potential regulation effects on the proliferation and differentiation of hematopoietic stem cells and leukemic cells [16]. In the present study, the study group showed lower IL-6 and TNF-α levels versus the control group, suggesting that imatinib mesylate effectively reduced the IL-6 and TNF-α levels and regulated the proliferation and differentiation of hematopoietic stem cells and leukemic cells.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of imatinib mesylate in combination with radiotherapy in acute leukemia, and the effect on immune function

Zhang¹

2022

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To evaluate the clinical efficacy of imatinib mesylate plus radiotherapy for the treatment of acute leukemia and its effect on immune function.Methods: A retrospective study was conducted on 88 patients with acute leukemia admitted to Zhuji Affiliated Hospital of Shaoxing University between July 2017 and July 2021. They were assigned (randomly, 1:1) to a control group (radiotherapy) or a study group (imatinib mesylate plus radiotherapy) according to different treatment regimens. Outcome measures assessed included the clinical efficacy of the treatments in the patients and their immune functions.Results: The two groups did not show any significant differences with regard to general patient profiles. After treatment, both groups presented reduced white blood cell (WBC) and platelet count (PLT) and elevated red blood cells count (RBC). The level of hemoglobin (Hb) level showed a slight decline in the control group but a significant increase in the study group (p < 0.05). The study group showed better improvement in the levels of WBC, PLT, RBC, and Hb than the control group (p < 0.05). The absolute values of peripheral blood mature neutrophils decreased in both groups after treatment, down to the lowest level at week 2, but rebounded, with higher absolute values in the study group at weeks 2, 3, and 4 of treatment (p < 0.05). Imatinib mesylate plus radiotherapy was associated with higher efficacy, compared with radiotherapy alone (p < 0.05).Conclusion: Radiotherapy plus imatinib mesylate effectively enhances the immune functions of acute leukemia patients, mitigates inflammatory responses, alleviates clinical symptoms, and boosts clinical efficacy. Further clinical trials are, however, required prior to general application in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of imatinib mesylate in combination with radiotherapy in acute leukemia, and the effect on immune function

Zhang¹

2022

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

“…Figure3. Mechanism of action of Imatinib, binding to the ATP binding site and preventing phosphorylation(Karasu et al, 2021) …”

mentioning

confidence: 99%

A Discussion of Chronic Myeloid Leukemia

Shen

2023

JIMR

View full text Add to dashboard Cite

Chronic Myeloid Leukemia (CML) is a triphasic hematological malignancy characterized by the presence of the abnormal Philadelphia chromosome, linked to causing uncontrolled myeloid cell proliferation in the bone marrow and marked changes in the peripheral blood and bone marrow microenvironments. The discovery of the BCR-ABL1 fusion oncogene from the balanced translocation of chromosomes 9 and 22, creating the Philadelphia chromosome, and its encoded tyrosine kinase protein has been linked to causing uncontrolled cell proliferation, leading to a subsequent development of tyrosine kinase inhibitors (TKI). TKIs, along with traditional chemotherapy drugs and interferon treatment, have revolutionized CML treatment, enabling deep remissions and prolonging of the disease’s chronic phase. This review will introduce CML and comprehensively explore the epidemiology, molecular basis, pathology, diagnostic approaches, and therapeutic strategies for CML, including their mechanisms of action and challenges, such as TKI resistance, with a focus on TKIs as the workhorses of CML therapy. By reviewing the current known literature, this paper aims to contribute to and guide the pursuit of new knowledge and research.

show abstract

Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy

Cited by 2 publications

References 29 publications

Efficacy of imatinib mesylate in combination with radiotherapy in acute leukemia, and the effect on immune function

Efficacy of imatinib mesylate in combination with radiotherapy in acute leukemia, and the effect on immune function

A Discussion of Chronic Myeloid Leukemia

Contact Info

Product

Resources

About